In another sign of its commitment to immunology, Eli Lilly has entered into a licensing and research collaboration with ImmuNext to develop immunometabolism therapies for the treatment of autoimmune diseases. The deal comes less than a year after Lilly acquired ARMO BioSciences for its Phase III immunotherapy, pegilodecakin, for the treatment of pancreatic cancer and just months after Lilly partnered up with Aduro Biotech in December 2018 to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which can modulate the immune response associated with various autoimmune diseases.